Table 1

Cohort characteristics at baseline

Characteristic

Baseline value


Gender

Female

Male

(N = 9040)

5962 (66)

3078 (34)


Age (years)

< 25 years

25-34 years

35-44 years

45-54 years

> 55 years

(N = 9040)

551 (6.1)

3822 (42.3)

3216 (35.5)

1173 (13.0)

277 (3.1)


WHO AIDS classification

Stage 1

Stage 2

Stage 3

Stage 4

(N = 8714)

4086 (46.9)

1310 (15)

2507 (28.8)

811 (9.3)


HAART

d4T/3TC/EFV

d4T/3TC/NVP

d4T/3TC/Kaletra

AZT containing regimen

TDF containing regimen

other

(N = 9040)

7138 (79)

690 (7.6)

669 (7.4)

308 (3.4)

59 (0.7)

176 (1.9)


BMI (kg/m2)

22.4 ± 5.0 (N = 7010)


CD4 count (cells/mm3)

81 (29-149) (N = 7605)


Follow up time on HAART (months)

19.0 (9.1-31.6) (N = 9040)


Data is expressed as N (%) except for BMI (mean ± SD), CD4 count (median, IQR) and follow up time on HAART (median, IQR). WHO, World Health Organization, d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; kaletra, ritonavir/lopinavir; AZT, zidovudine; TDF, tenofovir.

Menezes et al. BMC Infectious Diseases 2011 11:244   doi:10.1186/1471-2334-11-244

Open Data